Crossmark

Trivalent chromium versus baricitinib for rheumatoid arthritis treatment: first phase 2/3 randomized controlled trial, is trivalent chromium the upcoming immune-modulator?

Crossref DOI link: https://doi.org/10.1007/s10787-024-01515-x

Published Online: 2024-07-19

Published Print: 2024-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hassouna, Sally S. https://orcid.org/0000-0002-7259-5678
Abdel-Moniem, Omneya Mohamed-Ayman
Funding

Funding for this research was provided by:

Alexandria University
License Information

Text and Data Mining valid from 2024-07-19

Version of Record valid from 2024-07-19
More Information

Article History

Received: 28 May 2024

Accepted: 12 June 2024

First Online: 19 July 2024

Declarations

:

: Not applicable.

: Ethical approval was obtained from Ethics Committee, Faculty of Medicine, Alexandria University, Egypt for performing this trial (IRB No.: 00012098- FWA No.: 00018699, Serial number: 040457) and the study was registered in ClinicalTrials.gov with ID: NCT05545020.

: Not applicable.

Document is current

Any future updates will be listed below